Avacta Therapeutics
  • About
  • Our Science
  • Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • About
    • About Avacta
    • Leadership
    • Scientific Resources
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Leadership
    • Scientific Resources
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
Home News
filter by: view all | Blogs | Diagnostics | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics

News

31 May 2024

Posting of Annual Report and Notice of AGM

Investors
23 May 2024

Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta’s AVA6000 Phase 1 trial

Investors | Therapeutics
30 Apr 2024

Preliminary Results for the Year Ended 31 December 2023

Investors
30 Apr 2024

Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group

Investors
25 Apr 2024

Research and Development Spotlight Series – Episode 2

Blogs | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
23 Apr 2024

Block Listing Application to AIM

Investors
23 Apr 2024

Notice of Results

Investors
22 Apr 2024

Issue of Equity and Total Voting Rights

Investors
09 Apr 2024

Christina Coughlin – AACR 2024 – AVA6000 data presentation

Blogs | Investors | Podcasts and Videos | Therapeutics
09 Apr 2024

Avacta Therapeutics Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 at the AACR Annual Meeting Demonstrating Clinical Proof-of-Concept Showing Multiple Patient Responses

Investors | Therapeutics

Posts navigation

Older posts
Newer posts
Avacta Therapeutics
  • Diagnostics
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Corporate Responsibility
  • Contact Us

Avacta Group plc

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3911 0353

Investor Enquiries

ICR Consilium
85 Gresham Street
London
EC2V 7NQ

 

Email

Twitter | Linkedin

©2025 Avacta Therapeutics. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok